Bakuchiol’s Case Rests on Forty-Four People and Twelve Weeks

Bakuchiol is sold as the gentler, plant-derived answer to retinol. I understand the appeal completely — wrinkle and pigment improvement without spending six weeks flaking is a trade almost anyone would take. The question is whether the evidence is offering that trade or whether the marketing is offering it on the evidence’s behalf.

Parallel path, not identical mechanism

Bakuchiol is a meroterpene phenol from Psoralea corylifolia. It can influence some retinol-adjacent gene-expression pathways, but it is not a retinoid and does not work by simply becoming “plant retinol.” Two molecules arriving at a similar-looking outcome are not interchangeable, and the nickname quietly does the work that a mechanism ought to.

Forty-four people, twelve weeks, and a genuinely clean design

The cleanest study is the 2019 Dhaliwal randomized, double-blind trial: 44 participants, 12 weeks, 0.5% bakuchiol twice daily versus 0.5% retinol once daily. Both groups improved wrinkle surface area and hyperpigmentation, with more scaling and stinging reported in the retinol group.

That is a real result and I am not going to be sniffy about it. Double-blind, active comparator, measured endpoints — most trend ingredients would be delighted to have it. But it is one trial of forty-four people, and a category is currently being built on top of it.

The supporting literature does not hold that weight. A 2024 systematic review found 15 human clinical trials, but most were open-label, many used combination formulas, and the designs were too heterogeneous for a clean pooled answer. Fifteen trials sounds like a lot until you learn how few of them were blinded or tested bakuchiol on its own. “There is a promising trial” and “bakuchiol is clinically equivalent to retinoids” are not the same sentence, and only one of them is printed on a box.

Gentleness is the trade being offered

If you have repeatedly failed a retinoid on irritation, a gentler product you will actually use beats a theoretically stronger one that spends half the year in a drawer. Adherence is not a consolation prize; it is how topical results happen at all.

Just be clear about what you are buying. That is an adherence advantage, not proof that the evidence base has caught up with tretinoin or well-studied retinol. You are trading a large literature for a small one, usually at a higher price, in exchange for being able to stay on the thing.

Pregnancy is not a free pass

Bakuchiol is not a retinoid, and that fact establishes nothing about pregnancy safety. Human pregnancy-safety data are insufficient. If pregnancy, breastfeeding or preconception is the reason a retinoid is off the table, do not treat bakuchiol as automatically cleared — “not the risky molecule” is not the same as “studied and found safe,” and this one belongs in a clinician conversation rather than a comment thread.

Who might reasonably prefer it

Someone who has genuinely failed retinoids on irritation, wants a gentler anti-photoaging option, and is comfortable with a smaller evidence base. Not someone looking for a stealth upgrade on prescription tretinoin, which this is not. Retinaldehyde, a lower-strength retinoid, better moisturization, a slower schedule, or simply excellent sunscreen may solve the actual problem more directly and more cheaply.

Buy the tolerability, not the nickname

Take the 2019 trial seriously. Do not let it stand in for a category it cannot cover. Gentler is a real, useful, purchasable claim — and if a bottle is charging you retinoid-replacement prices, it is charging for the word equivalent, which forty-four people over twelve weeks did not buy for it.

Sources: Dhaliwal et al., 2019 randomized double-blind bakuchiol-versus-retinol trial (PMID 29947134); Fanning et al., 2024 systematic review of human topical bakuchiol trials (PMID 38564402). Reviewed August 2026. General education, not individualized medical advice.

Continue: The Verdict Index